Although a phase 2 trial in treatment-naïve Asian patients with NSCLC did not show statistically significant differences in overall response rate (ORR) and progression-free survival (PFS) by adding ficlatuzumab to gefitinib in the intention-to-treat (ITT) population, the combination of ficlatuzumab and gefitinib demonstrated a trend toward ORR and PFS improvement in a subset of patients with both EGFR-sensitizing mutations and low MET biomarker levels. This evidence concerns the gene MET and non-small cell lung carcinoma.